FHI 360 | MedPath

Daré Bioscience and Theramex Partner to Develop Novel Biodegradable Contraceptive Implant

3 months ago

• Daré Bioscience and Theramex have entered into a co-development agreement for Casea S, a first-in-category biodegradable contraceptive implant designed to last 18-24 months. • The innovative implant eliminates the need for surgical removal, addressing a key barrier in current contraceptive implants while offering women a convenient, long-acting contraceptive option. • A foundation-funded Phase 1 trial is currently underway to evaluate the pharmacokinetics, removability, safety, and tolerability of Casea S.

USAID Funding Freeze Threatens HIV Treatment Programs Across Africa

3 months ago

• The recent USAID stop-work order has halted critical HIV research and treatment programs in Nigeria and Uganda, affecting millions of patients who depend on aid-funded antiretroviral therapy. • Despite an emergency waiver for "life-saving" humanitarian assistance, many USAID-funded clinics remain closed, with over 200 HIV prevention staff in Uganda placed on administrative leave. • The suspension threatens Africa's progress toward the global "95-95-95" HIV goals, with concerns about medicine stockpiles running out and potential long-term withdrawal of support.